BiotechTube

Sonelokimab + Placebo

Phase 3Active
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hidradenitis Suppurativa

Conditions

Hidradenitis Suppurativa

Trial Timeline

May 15, 2024 → Jun 17, 2026

NCT ID
NCT06411899

About Sonelokimab + Placebo

Sonelokimab + Placebo is a phase 3 stage product being developed by MoonLake Immunotherapeutics for Hidradenitis Suppurativa. The current trial status is active. This product is registered under clinical trial identifier NCT06411899. Target conditions include Hidradenitis Suppurativa.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT06641076Phase 3Active
NCT06411899Phase 3Active
NCT06411379Phase 3Active

Competing Products

20 competing products in Hidradenitis Suppurativa

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
72
SonelokimabMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab (M1095) + AdalimumabMoonLake ImmunotherapeuticsPhase 2
47
Eltrekibart + PlaceboEli LillyPhase 2
52
Placebo + LY3041658Eli LillyPhase 2
52
Placebo + AdalimumabAbbVieApproved
85
Lutikizumab + PlaceboAbbViePhase 3
77
AdalimumabAbbViePre-clinical
23
Upadacitinib + PlaceboAbbViePhase 3
77
adalimumab + placeboAbbViePhase 3
77
LutikizumabAbbViePhase 2
52
adalimumabAbbViePhase 3
77
Lutikizumab + PlaceboAbbViePhase 2
52
Risankizumab + Placebo for risankizumabAbbViePhase 2
52
adalimumabAbbViePhase 3
77
adalimumab + placeboAbbViePhase 3
77
Upadacitinib + PlaceboAbbViePhase 2
52
MEDI8968 + SalineAstraZenecaPhase 2
52
AnifrolumabAstraZenecaPhase 2
52

Other Products from MoonLake Immunotherapeutics

SonelokimabPhase 3
72
Sonelokimab + Placebo + RisankizumabPhase 3
72
SonelokimabPhase 3
72
SonelokimabPhase 3
72
Sonelokimab + PlaceboPhase 3
72